Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17411276 | 0.84 | LMNA (0.69) | LMNANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL6646127 | 0.83 | LMNA (0.67) | LMNANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL3935660 | 0.83 | LMNA (0.67) | LMNANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL19105534 | 0.81 | LMNA (0.65) | LMNANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL942312 | 0.80 | LMNA (1.00) | LMNANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL5916430 | 0.79 | LMNA (0.49) | LMNANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL16756561 | 0.79 | LMNA (0.61) | LMNANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL28618636 | 0.79 | LMNA (0.71) | LMNANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL15722232 | 0.76 | HRH4 (0.50) | ALDH1A1USP2HSD17B10CYP1A2TSHR | |
| SCHEMBL6644916 | 0.75 | LMNA (0.56) | LMNANPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1812974-B | N- {' 4-substituted piperazine-1-sulfonylmethyl alkyl } -N-hydroxyformamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB | 2011-06-29 | — | — | CN | disclosed |
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| EP-1644340-B1 | N-[({'4-SUBSTITUTED PIPERAZINE-1-YL}SULFONYLMETHYL)ALKYL]-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| US-7153857-B2 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
| CN-1812974-A | N- {' 4-substituted piperazine-1-sulfonylmethyl alkyl } -N-hydroxyformamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| EP-1644340-A1 | N-{'4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL]ALKYL}-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005000822-A1 | N-{‘4-SUBSTITUTED PIPERAZINE-1-SULFONYLMETHYL!ALKYL}-N-HYDROXYFOMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-01-06 | — | — | WO | disclosed |
| US-20040220185-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
| EP-1417201-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003014111-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | LMNA 3270/4885NPC1 1779/4885RAB9A 2952/4885 |
| US-20040220185-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | LMNA 2980/4885NPC1 1261/4885RAB9A 3128/4885 |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | MMP26, MMP9, MMP3 | LMNA 903/4885NPC1 406/4885RAB9A 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.